 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Adit Ginde and Matthew Wynia.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.425 |
|
|
|
-
Wynia MK, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele JD, Stocker HR, Wogu AF, Zane RD, Sokol RJ, Ginde AA. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2023 05; 163(5):1061-1070.
Score: 0.866
-
Wynia MK, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Stocker HR, Wogu AF, Zane RD, Sokol RJ, Ginde AA. Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. medRxiv. 2022 Jan 11.
Score: 0.820
-
Molina KC, Kennerley V, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Aggarwal NR, Ginde AA. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5. Int J Infect Dis. 2023 Jul; 132:34-39.
Score: 0.224
-
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023 06; 23(6):696-705.
Score: 0.221
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Wogu AF, Wynia MK, Zane RD, Ginde AA. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. J Infect Dis. 2022 12 13; 226(12):2129-2136.
Score: 0.218
-
Douin DJ, Wogu AF, Beaty LE, Carlson NE, Bennett TD, Aggarwal NR, Mayer DA, Ong TC, Russell S, Steele J, Peers JL, Molina KC, Wynia MK, Ginde AA. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients. BMC Infect Dis. 2022 Nov 07; 22(1):818.
Score: 0.217
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. Int J Infect Dis. 2023 Mar; 128:310-317.
Score: 0.216
-
Kwan BM, Sobczak C, Beaty L, Wynia MK, DeCamp M, Owen V, Ginde AA. Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable Access. J Gen Intern Med. 2022 10; 37(13):3426-3434.
Score: 0.212
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Wogu AF, Wynia MK, Zane RD, Ginde AA. Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. medRxiv. 2022 Apr 05.
Score: 0.208
-
Hamer MK, Sobczak C, Whittington L, Bowyer RL, Koren R, Begay JA, Lum HD, Ginde AA, Wynia MK, Kwan BM. Real-world data to evaluate effects of a multi-level dissemination strategy on access, outcomes, and equity of monoclonal antibodies for COVID-19. J Clin Transl Sci. 2023; 7(1):e258.
Score: 0.058
-
Fish LE, Bendelow T, Gardiner S, Wynia MK, Kwan BM, Hamer MK, Ginde AA, Hanratty R. A multimodal strategy to improve race/ethnic group equity in administration of neutralizing monoclonal antibody treatment for COVID-19 outpatients. J Clin Transl Sci. 2023; 7(1):e37.
Score: 0.055
-
Hamer MK, Alasmar A, Kwan BM, Wynia MK, Ginde AA, DeCamp MW. Referrals, access, and equity of monoclonal antibodies for outpatient COVID-19: A qualitative study of clinician perspectives. Medicine (Baltimore). 2022 Dec 16; 101(50):e32191.
Score: 0.055
-
Kwan BM, Sobczak C, Gorman C, Roberts S, Owen V, Wynia MK, Ginde AA, Pena-Jackson G, Ziegler O, Ross DeCamp L. "All of the things to everyone everywhere": A mixed methods analysis of community perspectives on equitable access to monoclonal antibody treatment for COVID-19. PLoS One. 2022; 17(11):e0274043.
Score: 0.054
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|